Results 261 to 270 of about 242,034 (343)

The return of metabolism: biochemistry and physiology of glycolysis

open access: yesBiological Reviews, EarlyView.
ABSTRACT Glycolysis is a fundamental metabolic pathway central to the bioenergetics and physiology of virtually all living organisms. In this comprehensive review, we explore the intricate biochemical principles and evolutionary origins of glycolytic pathways, from the classical Embden–Meyerhof–Parnas (EMP) pathway in humans to various prokaryotic and ...
Nana‐Maria Grüning   +19 more
wiley   +1 more source

Insights Into Macrophage Ferroptosis: Implications for Atherosclerosis

open access: yesCell Proliferation, EarlyView.
Macrophage ferroptosis drives atherosclerosis by enhancing oxidative stress and inflammation, accelerating plaque progression and instability. Targeting macrophage ferroptosis presents a promising therapeutic strategy for atherosclerosis treatment.
Xiehui Chen, Xiangbo Liu, Changchun Zeng
wiley   +1 more source

Impact of Serum Uric Acid Levels on the Diagnosis of Coronary Vasospastic Angina. [PDF]

open access: yesJ Clin Med
Tamura N   +5 more
europepmc   +1 more source

Defective high‐density lipoprotein lipoprotection in type 2 diabetes during acute myocardial infarction is rescued by apolipoprotein M/sphingosine‐1‐phosphate loading

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Mortality of patients with type 2 diabetes (T2D) after acute myocardial infarction (AMI) is tremendous and massively increased compared to non‐T2D individuals. The reasons are unclear. High‐density lipoprotein (HDL) conducts lipoprotection during AMI, leading to improved outcomes.
Jens Vogt   +12 more
wiley   +1 more source

Cross-sectional and longitudinal associations between pan-immune-inflammation value and serum uric acid. [PDF]

open access: yesFront Endocrinol (Lausanne)
Lu ZL   +6 more
europepmc   +1 more source

Effect of empagliflozin on urinary albumin excretion and hypoxic biomarkers in early diabetic kidney disease: A randomised double‐blind, placebo‐controlled trial

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims The precise mechanism of sodium glucose co‐transporter 2 (SGLT2) inhibitor on reno‐protective effect has been still unclear. In this study, we hypothesised that SGLT2 inhibitor prevents diabetic kidney disease via reduction of hypoxia‐induced factors.
Hisashi Makino   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy